RxDoctor Payments Data

Nancy Serbellon

Adult Health · New York, NYNPI 1225469216

Payments from drug & device makers

$2,135in general payments, 2019–2025

Across 73 payments — averaging $29.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$1K
  • Urovant Sciences Inc$347
  • Hollister Incorporated$292
  • Novo Nordisk$117
  • AstraZeneca$110
  • Boston Scientific$43
  • plus $145 from 5 others

What the payments were for

  • Food & beverage$2,135100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sumitomo Pharma America, Inc.39$1,081
Urovant Sciences Inc12$347
Hollister Incorporated12$292
Novo Nordisk1$117
AstraZeneca1$110
Boston Scientific1$43
ABC Home Medical Supply, Inc.2$41
Medtronic2$37
Axonics, Inc.1$24
Astellas Pharma US Inc1$23
AbbVie1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,135 in reported general payments places this provider in the 80th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$23,232
Medicare patients
123
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron600$513,221
MyrbetriqMirabegron149$128,569
Lupron DepotLeuprolide Acetate22$125,935
EligardLeuprolide Acetate41$51,471
Estradiol204$10,574
Tamsulosin Hcl645$9,963
Trospium Chloride80$5,409
Trospium Chloride ErTrospium Chloride20$3,422
Silodosin32$2,282
Finasteride236$1,948
Methenamine Hippurate16$1,904
Alfuzosin Hcl ErAlfuzosin Hcl105$1,838
Oxybutynin Chloride ErOxybutynin Chloride32$898
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$711
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst35$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,081$513,221600 claims
Astellas Pharma US IncMyrbetriq$23$128,569149 claims
AbbVieLupron Depot$21$125,93522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,828 adult health providers in New York.

Other adult health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →